Labcorp Holdings Inc. $LH Stock Holdings Increased by Wedge Capital Management L L P NC

Key Points

• Wedge Capital boosted its stake in Labcorp by 15.5% in Q4 to 110,675 shares (about $27.77M), representing roughly 0.13% of the company, while institutional investors own about 95.94% of the stock.
• Labcorp beat quarterly EPS ($4.07 vs. $3.95) with revenue up 5.6% year-over-year, provided FY2026 guidance of $17.55–$18.25 EPS, and carries a consensus analyst rating of Moderate Buy with an average target of ~$304.82.

Wedge Capital Management L L P NC boosted its holdings in shares of Labcorp Holdings Inc. (NYSE:LH - Free Report) by 15.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 110,675 shares of the medical research company's stock after purchasing an additional 14,892 shares during the period. Wedge Capital Management L L P NC owned approximately 0.13% of Labcorp worth $27,766,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in LH. HBK Sorce Advisory LLC increased its holdings in shares of Labcorp by 4.3% in the third quarter. HBK Sorce Advisory LLC now owns 916 shares of the medical research company's stock valued at $254,000 after buying an additional 38 shares in the last quarter. Pure Financial Advisors LLC boosted its stake in shares of Labcorp by 3.9% during the 3rd quarter. Pure Financial Advisors LLC now owns 1,017 shares of the medical research company's stock worth $292,000 after acquiring an additional 38 shares in the last quarter. Hantz Financial Services Inc. grew its holdings in shares of Labcorp by 48.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company's stock worth $35,000 after acquiring an additional 40 shares during the last quarter. Burney Co. grew its holdings in shares of Labcorp by 0.5% in the 3rd quarter. Burney Co. now owns 8,819 shares of the medical research company's stock worth $2,532,000 after acquiring an additional 42 shares during the last quarter. Finally, Advisor OS LLC raised its position in shares of Labcorp by 5.4% during the third quarter. Advisor OS LLC now owns 821 shares of the medical research company's stock worth $236,000 after purchasing an additional 42 shares during the period. 95.94% of the stock is currently owned by institutional investors.

Labcorp Stock Performance

Shares of LH stock opened at $264.52 on Friday. The company has a market capitalization of $21.80 billion, a price-to-earnings ratio of 25.29, a P/E/G ratio of 1.83 and a beta of 1.01. Labcorp Holdings Inc. has a 1-year low of $209.38 and a 1-year high of $293.72. The company has a current ratio of 1.42, a quick ratio of 1.23 and a debt-to-equity ratio of 0.60. The stock's fifty day simple moving average is $274.20 and its 200-day simple moving average is $269.23.

Labcorp (NYSE:LH - Get Free Report) last announced its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The firm had revenue of $3.52 billion during the quarter, compared to the consensus estimate of $3.56 billion. During the same period in the prior year, the business earned $3.45 EPS. The business's revenue for the quarter was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. On average, sell-side analysts predict that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Friday, February 27th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.1%. The ex-dividend date was Friday, February 27th. Labcorp's dividend payout ratio (DPR) is currently 27.53%.

Insider Activity at Labcorp

In other news, CEO Adam H. Schechter sold 8,705 shares of the business's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the transaction, the chief executive officer directly owned 80,773 shares in the company, valued at $22,613,209.08. The trade was a 9.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Der Vaart Sandra D. Van sold 548 shares of the company's stock in a transaction on Friday, February 27th. The stock was sold at an average price of $284.91, for a total transaction of $156,130.68. Following the completion of the transaction, the executive vice president directly owned 2,579 shares in the company, valued at $734,782.89. This trade represents a 17.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 16,113 shares of company stock valued at $4,547,450. Company insiders own 0.84% of the company's stock.

Wall Street Analyst Weigh In

LH has been the subject of a number of recent analyst reports. Weiss Ratings upgraded Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, February 10th. Piper Sandler boosted their price objective on Labcorp from $270.00 to $300.00 and gave the stock a "neutral" rating in a report on Tuesday, February 24th. Robert W. Baird upped their price objective on shares of Labcorp from $313.00 to $326.00 and gave the company an "outperform" rating in a research note on Wednesday, February 18th. JPMorgan Chase & Co. lifted their target price on shares of Labcorp from $319.00 to $330.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 18th. Finally, Morgan Stanley restated an "overweight" rating on shares of Labcorp in a report on Tuesday, February 17th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $304.82.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.